Compare Cytokinetics Inc (CYTK) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Suncor Energy Inc. — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Suncor Energy Inc. trades at $70.84 (market cap $80.03B). The key difference: Suncor Energy Inc. is far larger — about 9.4× Cytokinetics Inc's market cap, and Suncor Energy Inc. pays a 2.49% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Suncor Energy Inc. for 57 Days on average.
| CYTK | SU | |
|---|---|---|
Market Cap | $8.50B | $80.03B |
Volume | 2,395,556 | 2,907,827 |
Sector | Health | Energy |
52-Week High | $87.26 | $71.87 |
52-Week Low | $54.76 | $38.17 |
Typical Hold Time | 19 Days | 57 Days |
Enterprise Value | $8.60B | $86.58B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Suncor Energy (SU) trades at $70.91, up 3.94% today, reflecting strong momentum near recent highs. The stock exhibits a bullish technical trend with support at $68 and resistance at $69. Fundamentally, SU maintains solid profitability with a 14.7% net income margin and attractive valuation at a P/E of 12.98. Recent Q2 2026 earnings beat expectations, and the company announced a $0.60 dividend for H2-2026. Cash flow remains robust, supporting shareholder returns via buybacks.
The outlook for SU is positive, driven by strong cash generation, debt reduction, and strategic asset sales. Investment appeal lies in its integrated model, shareholder returns, and exposure to global energy markets. Key risks include commodity price volatility, operational disruptions from weather, and execution of leadership transition. Analyst consensus is strongly bullish with 74% buy ratings, signaling confidence in continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
